› Forums › General Melanoma Community › Brain met year after braf/mek how to choose immuno
- This topic has 7 replies, 3 voices, and was last updated 4 years, 8 months ago by
jend013.
- Post
-
- December 19, 2020 at 2:46 pm
Hello, my husband has posted here before, but I am new. He may see this 🙂Background: 37 years old. Surgery for melanoma in parotid gland summer of 2018. One positive lymph node. Braf/mek inhibitor from August 2018-August 2019. NED from surgery until now.
Brain MRI showed a single 2cm spot in his brain. CT was clear.
Radiation started yesterday.
Treatment will start soon. The options we have been discussing have been the ipi/nivo combo, nivo alone, or nktr-214 trial. I was under the impression that we were dealing with maybe a 50% response rate, to 20%, to 50% based on the trials. I have read all of Bubble’s posts about the combo, combining immunotherapy with radation, etc. He was weighing effectiveness vs side effects. Seemed we were on the right track. THEN I ran across something last night that said in the ABC trial, when patients were stratified by prior braf/mek, the response rate dropped to like 16%. Shit.
How do we choose? Would we have access to any of the biomarkers to help? Do you think the fact that he quit braf/mek 1.5 years ago makes a difference? Has anyone one here had a good response to immunotherapy after targeted? Am I missing something? Is this a crapshoot?
- Replies
-
-
- December 19, 2020 at 3:13 pm
Hi hthttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1805453tps://ascopost.com/videos/esmo-2019-congress/georgina-long-on-melanoma-brain-metastases/ -
- December 19, 2020 at 3:15 pm
I am typing a reply but can not see what I am typing. Links above were to Dr. Long and checkmate 204 trial and the difference when prior targeted therapy use was 59% vs 51%.-
- December 24, 2020 at 4:18 pm
Here are those two links again, and the stats look like 59% vs51% for non targeted therapy vs previous targeted therapy. The NKTR-214 trial didn’t take brain met patients so I am not sure how that one got into your picks and it still hasn’t received approval though I do like the early data there seems to have been some issue with early data information. https://ascopost.com/videos/esmo-2019-congress/georgina-long-on-melanoma-brain-metastases/ https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805453
-
- December 19, 2020 at 8:45 pm
Thank you! I also found this: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.10016Says people who relapsed after targeted adjuvant have similar response rates to immunotherapy as first line in stage 4.
-
- December 24, 2020 at 4:18 pm
I will try links again. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805453 https://www.youtube.com/watch?v=ujXRRV8uRD8 -
- December 24, 2020 at 4:18 pm
https://ascopost.com/videos/esmo-2019-congress/georgina-long-on-melanoma-brain-metastases/Is this the link you wanted to share, Edster? I think the problem with the prior posting (if this one works) is that it was no longer up on the NEJM site…but is on the ASCO one. (FYI – your link worked on a prior post). You da best! celeste
-
- December 24, 2020 at 4:18 pm
https://ascopost.com/videos/esmo-2019-congress/georgina-long-on-melanoma-brain-metastases/https://ascopost.com/videos/esmo-2019-congress/georgina-long-on-melanoma-brain-metastases/
Is this the link you wanted to share, Edster? I think the problem with the prior posting (if this one works) is that it was no longer up on the NEJM site…but is on the ASCO one. (FYI – your link worked on a prior post). You da best! celeste
Okay….now the thing keeps telling me I’ve already said this, but has yet to post it. Will try again!!!
-
- You must be logged in to reply to this topic.